David Miller to Case-Control Studies
This is a "connection" page, showing publications David Miller has written about Case-Control Studies.
Connection Strength
0.268
-
Miller DP, Watkins SE, Sampson T, Davis KJ. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int J Chron Obstruct Pulmon Dis. 2011; 6:467-76.
Score: 0.086
-
Miller DP, De Vivo I, Neuberg D, Wain JC, Lynch TJ, Su L, Christiani DC. Association between self-reported environmental tobacco smoke exposure and lung cancer: modification by GSTP1 polymorphism. Int J Cancer. 2003 May 10; 104(6):758-63.
Score: 0.048
-
Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G. A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):204-11.
Score: 0.017
-
McCarty KM, Ryan L, Houseman EA, Williams PL, Miller DP, Quamruzzaman Q, Rahman M, Mahiuddin G, Smith T, Gonzalez E, Su L, Christiani DC. A case-control study of GST polymorphisms and arsenic related skin lesions. Environ Health. 2007 Feb 06; 6:5.
Score: 0.016
-
Zhou W, Park S, Liu G, Miller DP, Wang LI, Pothier L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Dietary iron, zinc, and calcium and the risk of lung cancer. Epidemiology. 2005 Nov; 16(6):772-9.
Score: 0.014
-
Thurston SW, Liu G, Miller DP, Christiani DC. Modeling lung cancer risk in case-control studies using a new dose metric of smoking. Cancer Epidemiol Biomarkers Prev. 2005 Oct; 14(10):2296-302.
Score: 0.014
-
Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett. 2004 Oct 08; 214(1):69-79.
Score: 0.013
-
Gong MN, Wei Z, Xu LL, Miller DP, Thompson BT, Christiani DC. Polymorphism in the surfactant protein-B gene, gender, and the risk of direct pulmonary injury and ARDS. Chest. 2004 Jan; 125(1):203-11.
Score: 0.013
-
Zhou W, Liu G, Miller DP, Thurston SW, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003 Apr; 12(4):359-65.
Score: 0.012
-
Su L, Liu G, Zhou W, Xu LL, Miller DP, Park S, Lynch TJ, Wain JC, Christiani DC. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):174-5.
Score: 0.012
-
Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, Su L, Christiani DC. Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1555-9.
Score: 0.012
-
Zhou W, Liu G, Thurston SW, Xu LL, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev. 2002 Jan; 11(1):15-21.
Score: 0.011